Skip to content

Released Jul 28, 2022, before the open

10-Q filed Aug 10, 2022, 38 days after period end · 0000078003-22-000094

Q2 2022 · 10-Q
Revenue$27.74B+46.8% vs Q2 2021+8.1% vs Q1 2022
Net Income$9.91B+78.1% vs Q2 2021+26.0% vs Q1 2022
EPS Diluted$1.73+76.5% vs Q2 2021+26.3% vs Q1 2022
Operating Cash Flowderived$8,170,000,000−27.7%
Free Cash Flowderived$7,419,000,000−31.1%
Margins · derived
Net margin35.7%+6.3 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$27.74B$18.90B$9.86B$13.26B
Net Income$9.91B$5.56B$3.49B$5.05B
EPS Diluted$1.73$0.98$0.62$0.89

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR